Geneva, April 20 -- International Clinical Trials Registry received information related to the study (NCT07523529) titled 'Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors' on April 5.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Beijing Biotech
Condition:
Advanced Unresectable
Metastatic
Intervention:
Biological: Autologous dual-target CAR-T cells selected from the predefined target library.
Drug: Fludarabine
Recruitment Status: Recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: March 2, 2026
Target Sample Size: 72
Countries of Recruitment:
China
To know more, visi...